指南与共识胸部肿瘤

ESMO关于EGFR突变非小细胞肺癌管理的专家共识声明

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.
指南 / 共识 · Ann Oncol · 2022-02-14

欧洲肿瘤内科学会(ESMO)于2021年以线上方式开展关于EGFR突变非小细胞肺癌的共识构建流程,由34位肺癌管理领域多学科专家参与。共识针对当前ESMO临床实践指南未详细覆盖且证据有限或存在冲突的议题制定推荐,涵盖组织与生物标志物分析、早期及局部晚期疾病、转移性疾病以及临床试验设计、患者视角及其他方面。

要点

  • 共识聚焦于ESMO临床实践指南未详细覆盖且证据有限或冲突的议题。
  • 专家小组分为四个工作组,分别负责组织与生物标志物分析、早期及局部晚期疾病、转移性疾病、临床试验设计及患者视角等议题。
  • 推荐由工作组制定后提交全体专家讨论、修订并投票,最终形成共识推荐及支持证据总结。

核心结论

  • 共识针对EGFR突变非小细胞肺癌管理中ESMO临床实践指南未详细覆盖且证据有限或存在冲突的议题提出了推荐。

研究设计与样本

  • 欧洲肿瘤内科学会(ESMO)于2021年举行线上共识构建流程,纳入34位肺癌管理领域多学科专家。
  • 专家小组分为四个工作组,分别负责组织与生物标志物分析、早期及局部晚期疾病、转移性疾病、临床试验设计及患者视角等议题。
  • 相关科学文献已预先审查,推荐由工作组制定后提交全体专家讨论、修订并投票。

主要发现

  • 本手稿呈现了制定的推荐,包括专家小组讨论的发现、共识推荐以及支持每项推荐的证据总结。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The European Society for Medical Oncology (ESMO) held a virtual consensus-building process on epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer in 2021. The consensus included a multidisciplinary panel of 34 leading experts in the management of lung cancer. The aim of the consensus was to develop recommendations on topics that are not covered in detail in the current ESMO Clinical Practice Guideline and where the available evidence is either limited or conflicting. The main topics identified for discussion were: (i) tissue and biomarkers analyses; (ii) early and locally advanced disease; (iii) metastatic disease and (iv) clinical trial design, patient's perspective and miscellaneous. The expert panel was divided into four working groups to address questions relating to one of the four topics outlined above. Relevant scientific literature was reviewed in advance. Recommendations were developed by the working groups and then presented to the entire panel for further discussion and amendment before voting. This manuscript presents the recommendations developed, including findings from the expert panel discussions, consensus recommendations and a summary of evidence supporting each recommendation.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Passaro A, Leighl N, Blackhall F, et al. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann Oncol. 2022. PMID: 35176458. doi:10.1016/j.annonc.2022.02.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。